Sachem Capital Corp. 6.875% Notes due 2024 Stock (AMEX: SACC)

Latest News for Sachem Capital Corp. 6.875% Notes due 2024 Stock (AMEX:SACC)

Sachem Capital Corp. 6.875% Notes due 2024

Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.05 by 60 percent. This is a 300 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $228.18 million which beat the analyst consensus estimate of $211.58 million by 7.85 percent. This is a 18.84 percent increase over sales of $192.01 million the same period last year.

Earnings

News

PAYO

Payoneer Global Q1 EPS $0.08 Beats $0.05 Estimate, Sales $228.18M Beat $211.58M Estimate

MasterCraft Boat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.23 by 60.87 percent. The company reported quarterly sales of $95.708 million which beat the analyst consensus estimate of $92.824 million by 3.11 percent. This is a 42.61 percent decrease over sales of $166.776 million the same period last year.

Earnings Beats

MCFT

MasterCraft Boat Q3 2024 Adj EPS $0.37 Beats $0.23 Estimate, Sales $95.708M Beat $92.824M Estimate

Biotech

Guidance

Health Care

General

ZVRA

As of March 31, 2024, Zevra Therapeutics' Cash, Cash Equivalents, And Investments Were $52.7M, April 5, 2024, The Company Announced Refinancing Of Existing Debt With Up To $100M In Committed Capital, Expected To Provide Cash Runway Into 2026

Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) reported quarterly earnings of $0.33 per share. This is a 38.89 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $119.69 million in sales this quarter. This is a 13.69 percent increase over sales of $105.28 million the same period last year.

Genie Energy Q1 EPS $0.33 Down From $0.54 YoY, Sales $119.69M Up From $105.28M YoY

Baird analyst Michael Halloran maintains Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) with a Outperform and raises the price target from $205 to $208.

Price Target

Analyst Ratings

Baird Maintains Outperform on Regal Rexnord, Raises Price Target to $208

Baird analyst Richard Eastman maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Outperform and lowers the price target from $310 to $304.

Baird Maintains Outperform on Rockwell Automation, Lowers Price Target to $304

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $50 price target.

Reiteration

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

SGHC

Super Group Announced That It Has Entered Into Definitive Agreements To Assume Full Control Of Its Sportsbook Software Technology Licensed By Apricot, Super Group's Long-standing Software Partner

Baird analyst Michael Halloran maintains Mueller Water Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) with a Neutral and raises the price target from $18 to $24.

Baird Maintains Neutral on Mueller Water Products, Raises Price Target to $24

Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. The company reported quarterly sales of $3.425 million which missed the analyst consensus estimate of $3.764 million by 8.99 percent. This is a 18.96 percent increase over sales of $2.879 million the same period last year.

Earnings Misses

Zevra Therapeutics Q1 2024 GAAP EPS $(0.40) Beats $(0.48) Estimate, Sales $3.425M Miss $3.764M Estimate

The Nasdaq 100 closed slightly lower on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
Robinhood
<ul>
<li>The Trade: Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) Chief Legal Officer Daniel Martin Gallagher Jr <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 12,500 shares</a> at an average price of $17.83. The insider received around $222,863 from selling those shares.</li>
<li>What's Happening: On May 6, Needham analyst John Todaro reiterated Robinhood Markets with a Hold.</li>
<li>What Robinhood Does: Robinhood Markets Inc is creating a modern financial services platform.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
<h3 class="wp-block-heading">First Solar</h3>
<ul>
<li>The Trade: First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) Director R Craig Kennedy <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 2,000 shares</a> at an average price of $196.73. The insider received around $393,456 from selling those shares.</li>
<li>What's Happening: On May 1, First Solar posted upbeat quarterly earnings.</li>
<li>What First Solar Does: First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects.</li>
</ul>
<h3 class="wp-block-heading">American Express</h3>
<ul>
<li>The Trade: American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) EVP – Controller Quinn Jessica Lieberman <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 3,140 shares</a> at an average price of $232.36. The insider received around $729,770 from selling those shares.</li>
<li>What's Happening: American Express declared a dividend on Series D Preferred Stock and regular quarterly dividend.</li>
<li>What American Express Does: American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products.</li>
</ul>
<h3 class="wp-block-heading">eBay</h3>
<ul>
<li>The Trade: eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) SVP, General Counsel &amp; Sec. Marie Oh Huber s<a href="https://www.benzinga.com/sec/insider-trades/">old a total of 49,070 shar</a>es at an average price of $49.63. The insider received around $2.44 million from selling those shares.</li>
<li>What's Happening: On May 1, eBay posted upbeat quarterly results.</li>
<li>What eBay Does: Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (29,900 global units at year-end 2023), Pizza Hut (19,866 units), Taco Bell (8,564 units), and The Habit Burger Grill (381 units).</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38692240/uber-lyft-and-3-stocks-to-watch-heading-into-wednesday">Uber, Lyft And 3 Stocks To Watch Heading Into Wednesday</a>

Short Ideas

Insider Trades

Pre-Market Outlook

Markets

EBAY

FSLR

HOOD

American Express, Robinhood And 2 Other Stocks Insiders Are Selling

Stephens &amp; Co. analyst Jim Salera reiterates The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) with a Overweight and maintains $9 price target.

STKS

Stephens & Co. Reiterates Overweight on The One Group Hospitality, Maintains $9 Price Target

SPLP

Steel Partners Holdings Q1 2024 EPS $1.50 Up From $1.09 YoY; Revenue $476.35M Up From $445.37M YoY

The company sees Q2 GMV of&nbsp;$85 million&nbsp;-&nbsp;$92 million,&nbsp;Adjusted EBITDA margin of (14%) - (9%).

DIBS

1stDibs Expects Q2 Net Revenue Of $21M-$22.3M, Est $20.867M

Outlook
The Company reaffirms its expectation to deliver positive adjusted EBITDA for full year 2024 along with another full year of positive operating cash flow. The Company also reiterates its expectation to realize restructuring-related cost savings of approximately&nbsp;$20.0 million&nbsp;in full year 2024 and&nbsp;$30.0 million&nbsp;thereafter compared to full year 2023.

CSTE

Caesarstone Reaffirms Outlook To Deliver Positive Adjusted EBITDA And Operating Cash Flow In 2024

Baird analyst Andrew Wittmann maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Outperform and lowers the price target from $168 to $163.

Baird Maintains Outperform on Jacobs Solutions, Lowers Price Target to $163

Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) (&quot;Alterity&quot; or &quot;the Company&quot;), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Baird analyst Ghansham Panjabi maintains Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Outperform and raises the price target from $100 to $110.

Baird Maintains Outperform on Intl Flavors & Fragrances, Raises Price Target to $110

PFGC

Performance Food Group Company Projects Q4 Net Sales Of $15B-$15.4B (Estimate: $15.6B), With Adjusted EBITDA Of $430M-$450M

Needham analyst Laura Martin reiterates comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) with a Buy and maintains $25 price target.

SCOR

Needham Reiterates Buy on comScore, Maintains $25 Price Target

A Wall Of Worry

Mortgage REITs: High-Yield Risk And Opportunity

Sachem Capital Corp. (SACH) Q2 2023 Earnings Call Transcript

Earnings Can't Cure Gloom

Sachem Capital Corp. (SACH) Q3 2023 Earnings Call Transcript

Sachem Capital: Fed About To Pivot, Fat 12.4% Yield Not Yet In Play

Reviewing My Fixed Income Assets And Strategies

Sachem Capital: I Am Sticking With The 9% Yielding Baby Bonds

Sachem Capital Corp. (SACH) Q4 2023 Earnings Call Transcript

Sachem Capital: Avoid The 12% Common Dividend Yield For The Bonds

AAIC

AAIN

ACRE

AFCG

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

AJXA

ANGL

AOMR

BALY

BCEFF

BCEPF

BCEXF

BCPPF

BECEF

BLDG

BRSP

BXMT

CHMI

CMBS

CNTY

CSSEN

CSWCZ

CUBE

EARN

ECCX

EICA

EPRT

EQIX

ESRT

EWRE

FBRT

FREL

FTAIN

GLPI

GPMT

GQRE

HASI

HAUS

HAUZ

HOMZ

IFGL

INDS

INVH

KBWY

KREF

LADR

MITT

MORT

NAIL

NETL

NREF

NTST

NURE

NYMT

NYMTL

NYMTM

NYMTN

NYMTZ

PAXS

PFFR

PLDGP

PMTU

PPTY

RDOG

REET

REFI

REGCO

REGCP

REIT

RESI

RIET

RILYG

RILYM

RILYZ

RITM

ROIC

ROOF

SACC

SACH

SBAC

SCCB

SCCC

SCCD

SCCE

SCCF

SCCG

SCHH

SEVN

SHYG

SRVR

STAG

STWD

TFSA

TPTA

TRTX

USRT

VICI

VIOO

VRAI

WELL

XLRE